A Study of BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis on Stable Methotrexate: The UNIFORM Study

Trial Profile

A Study of BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis on Stable Methotrexate: The UNIFORM Study

Suspended
Phase of Trial: Phase III

Latest Information Update: 09 May 2016

At a glance

  • Drugs Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms UNIFORM
  • Sponsors EPIRUS Biopharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 May 2016 Status changed from not yet recruiting to suspended based on cost-savings issues, as per EPIRUS media release.
    • 09 Feb 2016 According to an Epirus biopharmaceuticals media release, the company expects to submit a global filing for marketing approval of BOW015 in 2017, based on data from this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top